J&J discount offer wins NICE over to new use for Stelara

Johnson & Johnson has done some quick bargaining with the U.K.'s cost-effectiveness watchdogs. The National Institute for Health and Care Excellence (NICE) decided to reverse course on a new use for J&J's anti-inflammatory drug Stelara, thanks to a new discount offer.

NICE had stiff-armed Stelara (ustekinumab) as a treatment for psoriatic arthritis in May. The agency said that the drug was too pricey for its benefits, given other drugs available for the same disease, including J&J's ($JNJ) Simponi and Remicade, plus AbbVie's ($ABBV) Humira and Pfizer's ($PFE) Enbrel, PMLiVE reports.

But the agency says it has changed its mind, crediting a "patient access scheme" proposed by J&J's Janssen division, which markets the drug. The about-face isn't complete; NICE will only recommend Stelara for patients unable to use the other drugs or those who've tried at least one of them already. 

"NICE's decision supports Janssen's view that ustekinumab offers value to the NHS as well as being clinically valuable," said Janssen's U.K. medical director, Peter Barnes (as quoted by PMLiVE).

Stelara was already NICE-approved to treat plaque psoriasis. It's expected to hit $1.4 billion in global sales by 2015, despite a raft of new or soon-to-be-approved competitors in that market. Celgene's ($CELG) Otezla (apremalist) won approval in September for plaque psoriasis, and was already approved for psoriatic arthritis. Eli Lilly ($LLY), Novartis ($NVS), Amgen ($AMGN), AstraZeneca ($AZN), Merck ($MRK)--plus J&J--are working on their own next-gen psoriasis hopefuls.

- see the PMLiVE story

Special Reports: Top 10 pharma companies by 2014 employees - J&J | Top 10 best-selling drugs of 2013 - Humira - Enbrel - Remicade

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.